Anupam Rasayan India Limited’s Q1FY24 revenue at Rs 3,988 million, up 19% YoY

During the quarter, Anupam Rasayan signed an MoU with 3xper Innoventure Ltd., for the supply of targeted and identified new-age pharma molecules using continuous process.

Advertisement

Surat: Anupam Rasayan India Ltd. (BSE- 543275, NSE- ANURAS, ISIN: INE930P01018), one of India’s leading custom synthesis and specialty chemical player, has announced its financial results for the quarter ended June 30, 2023.

Speaking on the performance, Mr Anand Desai, Managing Director, Anupam Rasayan commented, “I am delighted at the consistent growth momentum of the Company against a challenging industry backdrop. Our consolidated revenue witnessed robust 19% Y-o-Y growth at Rs 3,988 Mn. While the falling prices of commodity agrochemicals are putting pressure on margins for the industry, our customised products and robust business model helped us deliver strong EBITDA margins of 29% in Q1 FY24.

During the quarter, Anupam Rasayan signed an MoU with 3xper Innoventure Ltd., for the supply of targeted and identified new-age pharma molecules using continuous process. The Company has also signed Letters of Intent (LOIs) worth Rs 40,660 Mn with Japanese and American MNCs for niche life sciences and specialty chemical molecules. These LOIs reinforce the growing confidence of global MNCs in our technical capabilities and think of us as the trusted partner of choice for high-end customised molecules. These LOIs improves our revenue visibility in the coming years.

Our order book remains strong despite a challenging external environment, giving us the confidence to deliver robust growth in FY24 while maintaining margins.”

Advertisement